UPDATE 2-U.S. FDA approves AcelRx Pharma's opioid pain drug [Reuters]
Trevena, Inc. (TRVN)
Last trevena, inc. earnings: 3/12 07:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.trevena.com/investor-relations
Company Research
Source: Reuters
FDA approves AcelRx Pharma's opioid pain drug | Reuters 3 Min Read (Reuters) - The U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc’s opioid-based treatment for pain to be used under strict medical supervision, with the agency’s chief highlighting reasons for the approval in a rare move. The regulator’s decision comes as the U.S. opioid crisis reaches epidemic levels, claiming lives of an estimated 130 Americans a day on average, according to the U.S. Centers for Disease Control and Prevention. “There are very tight restrictions being placed on the distribution and use of this product,” FDA Commissioner Scott Gottlieb said in a statement. Shares of AcelRx jumped 14.9 percent to $4.77 on Friday. The fast-acting drug, Dsuvia, will be used in hospitals, surgical centers and emergency departments, and its mechanism makes it easier to deliver where intravenous administration is not possible, the commissioner said. The Department of Defense has worked closely
Show less
Read more
Impact Snapshot
Event Time:
TRVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVN alerts
High impacting Trevena, Inc. news events
Weekly update
A roundup of the hottest topics
TRVN
News
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Trevena, Inc. (NASDAQ: TRVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Trevena Reports Fourth Quarter 2023 Results and Provides Corporate UpdateGlobeNewswire
TRVN
Earnings
- 8/14/23 - Miss
TRVN
Analyst Actions
- 4/2/24 - HC Wainwright
TRVN
Sec Filings
- 4/19/24 - Form PRE
- 4/9/24 - Form 8-K
- 4/3/24 - Form DEFA14A
- TRVN's page on the SEC website